May 6, 2022 06:18 AM EDTUpdated 10:52 AM

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter join in­sitro's SAB

Senior Editor

Editor

Sign up to read this article for free.

With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB